Tradename | Company | Number | Date | Products |
---|---|---|---|---|
XARELTO | Johnson & Johnson | N-022406 RX | 2011-07-01 | 4 products, RLD |
XARELTO | Johnson & Johnson | N-215859 RX | 2021-12-20 | 1 products, RLD, RS |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
pulmonary embolism | EFO_0003827 | D011655 | I26 |
venous thrombosis | HP_0004936 | D020246 | I82.40 |
Expiration | Code | ||
---|---|---|---|
RIVAROXABAN, XARELTO, JANSSEN PHARMS | |||
2025-06-20 | PED | ||
2025-02-23 | PED | ||
2024-12-20 | NP | ||
2024-08-23 | I-867 | ||
2023-09-10 | PED | ||
2023-04-11 | PED | ||
2023-03-10 | M-284 |
Patent | Expires | Flag | FDA Information |
---|---|---|---|
Rivaroxaban, Xarelto, Janssen Pharms | |||
10828310 | 2039-01-31 | U-3207, U-3208 | |
9539218 | 2034-02-17 | U-1953, U-1954, U-1955, U-1957, U-2143, U-2641, U-3285, U-3288, U-3289 | |
9415053 | 2024-11-13 | DP | U-1167, U-1200, U-1301, U-1302, U-2142, U-2435, U-2640, U-3205, U-3206, U-3284, U-3286, U-3287 |
7157456 | 2024-08-28 | DS, DP | U-1301, U-1302 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | 2 | 7 | 17 | 33 | 99 | 157 |
Venous thromboembolism | D054556 | EFO_0004286 | I74 | 3 | 11 | 26 | 7 | 34 | 78 |
Venous thrombosis | D020246 | HP_0004936 | I82.40 | 2 | 6 | 10 | 10 | 25 | 51 |
Stroke | D020521 | EFO_0000712 | I63.9 | — | 4 | 9 | 11 | 17 | 39 |
Pulmonary embolism | D011655 | HP_0002204 | I26 | — | 1 | 5 | 6 | 22 | 33 |
Hemorrhage | D006470 | MP_0001914 | R58 | 1 | 3 | 7 | 5 | 8 | 23 |
Acute coronary syndrome | D054058 | EFO_0005672 | — | — | 3 | 2 | 7 | 10 | 22 |
Coronary artery disease | D003324 | — | I25.1 | — | 2 | 2 | 10 | 6 | 20 |
Ischemic stroke | D000083242 | — | — | — | 4 | 4 | 1 | 11 | 18 |
Neoplasms | D009369 | — | C80 | 1 | 1 | 7 | 2 | 6 | 16 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 13 | 4 | 1 | — | 2 | 19 |
Intracranial hemorrhages | D020300 | EFO_0000551 | I62 | — | — | 2 | — | 3 | 5 |
Heart valve diseases | D006349 | EFO_0009551 | I08 | — | 2 | 2 | — | 2 | 5 |
Intracranial thrombosis | D020767 | — | — | 1 | 2 | 1 | — | 1 | 4 |
Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | 2 | 1 | 1 | — | 1 | 4 |
Renal insufficiency | D051437 | HP_0000083 | N19 | 1 | — | 1 | — | 1 | 3 |
Rheumatic heart disease | D012214 | EFO_1001161 | I09.9 | — | — | 3 | — | — | 3 |
Wounds and injuries | D014947 | — | T14.8 | — | — | 1 | — | 1 | 2 |
Drug-related side effects and adverse reactions | D064420 | — | T88.7 | — | — | 1 | — | 1 | 2 |
Cerebral hemorrhage | D002543 | — | — | — | 1 | 1 | — | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | — | 1 | — | — | 2 | 3 |
Hepatocellular carcinoma | D006528 | — | C22.0 | 1 | 1 | — | — | — | 2 |
Transient ischemic attack | D002546 | EFO_0003764 | G45.9 | — | 1 | — | — | 1 | 2 |
Brain ischemia | D002545 | EFO_0003883 | I67.82 | — | 1 | — | — | 1 | 2 |
Bariatric surgery | D050110 | — | — | 1 | 1 | — | — | — | 2 |
Stomach neoplasms | D013274 | EFO_0003897 | C16 | — | 1 | — | — | — | 1 |
Esophageal neoplasms | D004938 | — | C15 | — | 1 | — | — | — | 1 |
Duodenal neoplasms | D004379 | — | — | — | 1 | — | — | — | 1 |
Liver neoplasms | D008113 | EFO_1001513 | C22.0 | — | 1 | — | — | — | 1 |
Gastrointestinal stromal tumors | D046152 | EFO_0000505 | C49.A | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Therapeutic equivalency | D013810 | — | — | 4 | — | — | — | — | 4 |
Pharmacokinetics | D010599 | — | — | 2 | — | — | — | 1 | 3 |
Biological availability | D001682 | — | — | 2 | — | — | — | — | 2 |
Morbid obesity | D009767 | EFO_0001074 | — | 1 | — | — | — | — | 1 |
Coagulation protein disorders | D020147 | — | — | 1 | — | — | — | — | 1 |
Immune system diseases | D007154 | — | D89.9 | 1 | — | — | — | — | 1 |
Immunotherapy | D007167 | — | — | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Thrombophilia | D019851 | — | D68.59 | — | — | — | — | 2 | 2 |
Replacement arthroplasty knee | D019645 | — | — | — | — | — | — | 2 | 2 |
Replacement arthroplasty hip | D019644 | — | — | — | — | — | — | 2 | 2 |
Patient satisfaction | D017060 | — | — | — | — | — | — | 1 | 1 |
Patient participation | D010358 | — | — | — | — | — | — | 1 | 1 |
Oral surgery | D013515 | — | — | — | — | — | — | 1 | 1 |
Postoperative complications | D011183 | — | — | — | — | — | — | 1 | 1 |
Oral surgical procedures | D019647 | — | — | — | — | — | — | 1 | 1 |
Postoperative hemorrhage | D019106 | — | — | — | — | — | — | 1 | 1 |
Menorrhagia | D008595 | EFO_0003945 | N92.0 | — | — | — | — | 1 | 1 |
Drug common name | Rivaroxaban |
INN | rivaroxaban |
Description | Rivaroxaban is a monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-chlorothiophene-2-carboxylic acid with the amino group of 4-{4-[(5S)-5-(aminomethyl)-2-oxo-1,3-oxazolidin-3-yl]phenyl}morpholin-3-one. It is an anticoagulant used for prophylaxis of venous thromboembolism in patients with knee or hip replacement surgery. It has a role as an anticoagulant and an EC 3.4.21.6 (coagulation factor Xa) inhibitor. It is a member of thiophenes, an organochlorine compound, an oxazolidinone, a member of morpholines, a lactam, an aromatic amide and a monocarboxylic acid amide. Rivaroxaban is an orally bioavailable oxazolidinone derivative and direct inhibitor of the coagulation factor Xa with anticoagulant activity. Upon oral administration, rivaroxaban selectively binds to both free factor Xa and factor Xa bound in the prothrombinase complex. This interferes with the conversion of prothrombin (factor II) to thrombin and eventually prevents the formation of cross-linked fibrin clots. Rivaroxaban does not affect existing thrombin levels. |
Classification | Small molecule |
Drug class | antithrombotics, blood coagulation factor XA inhibitors |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | O=C(NC[C@H]1CN(c2ccc(N3CCOCC3=O)cc2)C(=O)O1)c1ccc(Cl)s1 |
PDB | — |
CAS-ID | 366789-02-8 |
RxCUI | — |
ChEMBL ID | CHEMBL198362 |
ChEBI ID | 68579 |
PubChem CID | 9875401 |
DrugBank | DB06228 |
UNII ID | 9NDF7JZ4M3 (ChemIDplus, GSRS) |